Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vermont Tech Scene.
Press releases published on April 23, 2025
Artax Biopharma to present Phase 2a data on Nck modulator AX-158, establishing novel mechanism of action in autoimmune disease at the 2025 SID Annual Meeting
GlobeNewswire
·
April 23, 2025
Late breaker abstract presentation to showcase clinical validation of first-in-class oral small molecule AX-158 in cohort of patients with psoriasis Full dataset to expand on previously announced topline results, reinforcing the potential of Nck modulation …
HP Announces 2025 Digital Equity Accelerator Cohort
GlobeNewswire
·
April 23, 2025
News Highlights: Eight nonprofit organizations in Greece, Indonesia, Nigeria, and Spain selected for the 2025 Digital Equity Accelerator. Organizations are serving disconnected adolescents and adults through digital skills training, education access, and …
Kindcard, Inc. Launches Payments Marketplace
GlobeNewswire
·
April 23, 2025
BOCA RATON, Fla., April 23, 2025 (GLOBE NEWSWIRE) -- Kindcard, Inc. (OTC Markets: KCRD) (“Kindcard” and the “Company”), an innovative FinTech and PayTech company which provides alternative payments solutions to businesses across a wide variety of merchant …
LambdaTest Launches Custom Widgets in BETA for Enhanced Dashboard Flexibility
GlobeNewswire
·
April 23, 2025
San Francisco, April 23, 2025 (GLOBE NEWSWIRE) -- LambdaTest, a unified agentic AI and cloud engineering platform, has announced the BETA release of Custom Widget Creation, a highly anticipated feature in its Insights platform. This new capability puts …
ModelOp Recognized in AI Governance Landscape Analyst Report
GlobeNewswire
·
April 23, 2025
CHICAGO, April 23, 2025 (GLOBE NEWSWIRE) -- ModelOp, the leading AI Governance software for enterprises, announced today its inclusion in Forrester’s new report, The AI Governance Solutions Landscape, Q2 2025. The report provides an overview of 22 vendors. …
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that data from the global Phase 3 VERITAC …
ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025
GlobeNewswire
·
April 23, 2025
ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025 Marseille, France, April 23, 2025 10:00 a.m. ET / 4:00 p.m. CET– ImCheck Therapeutics announced today an oral presentation at the upcoming …
XRP Whale Activity Rises as Investors Seek Steady Returns Through JA Mining’s Cloud Mining Platform
GlobeNewswire
·
April 23, 2025
JA Mining Image WARWICK, United Kingdom, April 23, 2025 (GLOBE NEWSWIRE) -- In recent days, activity on the XRP blockchain has revealed a quiet but notable trend: an increase in whale addresses—wallets holding over 10 million XRP—while exchange inflows …
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
- Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, April 23, 2025 ( …
SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …
WISeKey Expands Implementation of Digital Identity Solutions from Seychelles to Africa: Empowering Nations with Secure National ID Systems
GlobeNewswire
·
April 23, 2025
WISeKey Expands Implementation of Digital Identity Solutions from Seychelles to Africa: Empowering Nations with Secure National ID Systems Geneva, Switzerland – April 23, 2025 — WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a …
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025
GlobeNewswire
·
April 23, 2025
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that results from the REZILIENT1 study of zipalertinib …
Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting
GlobeNewswire
·
April 23, 2025
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of …
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today …
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
GlobeNewswire
·
April 23, 2025
MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on …
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today …
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
SAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at ASCO 2025 in Chicago, …
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
GlobeNewswire
·
April 23, 2025
— Oral presentation Tuesday, June 3, 2025 in Chicago — LOS ANGELES, April 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL …
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that updated data from …